ERK and PI3K signaling cascades induce Nrf2 activation and regulate cell viability partly through Nrf2 in human glioblastoma cells

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 715-722

  Cong, Zi Xiang ^a   Wang, Han Dong ^a   Wang, Jia Wei ^a   Zhou, Yuan ^a   Pan, Hao ^a   Zhang, Ding Ding ^a   Zhu, Lin ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Extracellular signal regulated kinase; Glioblastoma; Nrf2; Phosphatidylinositol 3 kinase

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR NRF2;

ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLIOBLASTOMA; HUMANS; MAP KINASE SIGNALING SYSTEM; NF-E2-RELATED FACTOR 2; PHOSPHATIDYLINOSITOL 3-KINASES; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION;

EID: 84879666141     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2485     Document Type: Article

References (41)

1. Furnari FB, Fenton T, Bachoo RM, et al: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710, 2007. (Pubitemid 350070717)
2. Nakada M, Kita D, Watanabe T, et al: Aberrant signaling pathways in glioma. Cancers 3: 3242-3278, 2011.
3. Wong ML, Kaye AH and Hovens CM: Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 14: 301-308, 2007. (Pubitemid 46335778)
4. Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF and Valerie K: Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8: 730-738, 2009.
5. Holand K, Salm F and Arcaro A: The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors. Curr Cancer Drug Targets 11: 894-918, 2011.
6. Li W and Kong AN: Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog 48: 91-104, 2009.
7. Lee JM and Johnson JA: An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 37: 139-143, 2004.
8. Lau A, Villeneuve NF, Sun Z, Wong PK and Zhang DD: Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270, 2008.
9. Niture SK, Kaspar JW, Shen J and Jaiswal AK: Nrf2 signaling and cell survival. Toxicol Appl Pharmacol 244: 37-42, 2010.
10. Rangasamy T, Guo J, Mitzner WA, et al: Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med 202: 47-59, 2005. (Pubitemid 41002909)
11. Chen XL and Kunsch C: Induction of cytoprotective genes through Nrf2/antioxidant response element pathway: a new therapeutic approach for the treatment of inflammatory diseases. Curr Pharm Des 10: 879-891, 2004.
12. Niture SK and Jaiswal AK: Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem 287: 9873-9886, 2012.
13. Reddy NM, Kleeberger SR, Bream JH, et al: Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. Oncogene 27: 5821-5832, 2008.
14. Zhao F, Wu T, Lau A, et al: Nrf2 promotes neuronal cell differentiation. Free Radic Biol Med 47: 867-879, 2009.
15. Cho HY, Reddy SP, Yamamoto M and Kleeberger SR: The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J 18: 1258-1260, 2004. (Pubitemid 39561569)
16. Sporn MB and Liby KT: NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12: 564-571, 2012.
17. Shah ZA, Li RC, Thimmulappa RK, et al: Role of reactive oxygen species in modulation of Nrf2 following ischemic reperfusion injury. Neuroscience 147: 53-59, 2007. (Pubitemid 46881103)
18. Cho HY, Jedlicka AE, Reddy SP, et al: Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 26: 175-182, 2002. (Pubitemid 34107870)
19. Calkins MJ, Johnson DA, Townsend JA, et al: The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal 11: 497-508, 2009.
20. He M, Siow RC, Sugden D, Gao L, Cheng X and Mann GE: Induction of HO-1 and redox signaling in endothelial cells by advanced glycation end products: a role for Nrf2 in vascular protection in diabetes. Nutr Metab Cardiovasc Dis 21: 277-285, 2011.
21. Shin S, Wakabayashi J, Yates MS, et al: Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol 620: 138-144, 2009.
22. Ohta T, Iijima K, Miyamoto M, et al: Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68: 1303-1309, 2008. (Pubitemid 351346836)
23. Stacy DR, Ely K, Massion PP, et al: Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck 28: 813-818, 2006. (Pubitemid 44320535)
24. Kim YR, Oh JE, Kim MS, et al: Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 220: 446-451, 2010.
25. Nioi P and Nguyen T: A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 362: 816-821, 2007. (Pubitemid 47390646)
26. Solis LM, Behrens C, Dong W, et al: Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16: 3743-3753, 2010.
27. Kweon MH, Adhami VM, Lee JS and Mukhtar H: Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem 281: 33761-33772, 2006. (Pubitemid 46036754)
28. Homma S, Ishii Y, Morishima Y, et al: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15: 3423-3432, 2009.
29. Baird L and Dinkova-Kostova AT: The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 85: 241-272, 2011.
30. Pan H, Wang H, Zhu L, Mao L, Qiao L and Su X: The role of Nrf2 in migration and invasion of human glioma cell U251. World Neurosurg: Nov 7, 2011 (Epub ahead of print).
31. Shibata T, Ohta T, Tong KI, et al: Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105: 13568-13573, 2008.
32. Yoo NJ, Kim HR, Kim YR, An CH and Lee SH: Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 60: 943-952, 2012.
33. Shibata T, Kokubu A, Gotoh M, et al: Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135: 1358-1368, 2008.
34. Padmanabhan B, Tong KI, Ohta T, et al: Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21: 689-700, 2006. (Pubitemid 43290735)
35. Banerjee P, Basu A, Datta D, Gasser M, Waaga-Gasser AM and Pal S: The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal. J Biol Chem 286: 33580-33590, 2011.
36. Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A and Hayes JD: Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene: Sep 10, 2012 (Epub ahead of print).
37. Nguyen T, Sherratt PJ, Huang HC, Yang CS and Pickett CB: Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J Biol Chem 278: 4536-4541, 2003. (Pubitemid 36800950)
38. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68: 7975-7984, 2008.
39. Wang XJ, Sun Z, Villeneuve NF, et al: Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29: 1235-1243, 2008. (Pubitemid 351958704)
40. Singh A, Bodas M, Wakabayashi N, Bunz F and Biswal S: Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal 13: 1627-1637, 2010.
41. McDonald JT, Kim K, Norris AJ, et al: Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res 70: 8886-8895, 2010.